Pharmacogenetics in oncology: 5-Fluorouracil and the dihydropyrimidine dehydrogenase;Pharmakogenetik in der onkologie: 5-Fluorouracil und die dihydropyrimidin-dehydrogenase

Deutsche Medizinische Wochenschrift

Volumn 133, Issue 28-29, 2008, Pages 1501-1504

  Lazar, A ^a   Jetter, Alexander ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

5 fluorouracil; Dihydropyrimidine dehydrogenase; Genotyping; Polymorphism; Toxicity

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; ANTINEOPLASTIC ANTIMETABOLITE;

DNA POLYMORPHISM; GENE MUTATION; GENOTYPE; PHARMACOGENETICS; REVIEW; AMINO ACID SUBSTITUTION; EXON; GENETIC POLYMORPHISM; GENETICS; HUMAN; METABOLISM; MUTATION; NEOPLASM;

AMINO ACID SUBSTITUTION; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); EXONS; FLUOROURACIL; GENOTYPE; HUMANS; MUTATION; NEOPLASMS; POLYMORPHISM, GENETIC;

EID: 47049088370     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1081098     Document Type: Review

References (18)

1. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000; 10: 217-223
2. Ezzeldin H, Johnson MR, Okamoto Y, Diasio R. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin Cancer Res 2003; 9: 3021-3028
3. Gross E, Ullrich T, Seck K, Mueller V, de Wit M, von Schilling C, Meindl A, Schmitt M, Kiechle M. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum Mutat 2003; 22: 498
4. Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 2002; 8: 768-774
5. Kouwaki M, Hamajima N, Sumi S, Nonaka M, Sasaki M, Dobashi K, Kidouchi K, Togari H, Wada Y. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. Clin Cancer Res 1998; 4: 2999-3004
6. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-487
7. Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S, Gamelin E. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 2006; 5: 2895-2904
8. Morel A, Boisdron-Celle M, Fey L, Laine-Cessac P, Gamelin E. Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma. Clin Biochem 2007; 40: 11-17
9. National Cancer Institute. National Cancer Institute Common Toxicity Criteria. http://www.fda.gov/cder/cancer/toxicityframe.htm
10. Ploylearmsaeng SA, Fuhr U, Jetter A. How may anticancer chemotherapy with fluorouracil be individualised? Clin Pharmacokinet 2006; 45: 567-592
11. Raida M, Schwabe W, Häusler P, van Kuilenburg AB, van Gennip AH, Behnke D, Höffken K. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 2001; 7: 2832-2839
12. Rich TA, Shepard RC, Mosley ST. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 2004; 22: 2214-2232
13. Ridge SA, Brown O, McMurrough J, Fernandez-Salguero P, Evans WE, Gonzalez FJ, McLeod HL. Mutations at codon 974 of the DPYD gene are a rare event. Br J Cancer 1997; 75: 178-179
14. Seck K, Riemer S, Kates R, Ullrich T, Lutz V, Harbeck N, Schmitt M, Kiechle M, Diasio R, Gross E. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res 2005; 11: 5886-5892
15. van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, van Lenthe H, De Abreu RA, Maring JG, Vreken P, van Gennip AH. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000; 6: 4705-4712
16. van Kuilenburg AB, Meinsma R, Zoetekouw L, van Gennip AH. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002; 12: 555-558
17. van Kuilenburg AB, Baars JW, Meinsma R, van Gennip AH. Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene. Ann Oncol 2003; 14: 341-342
18. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, Kerb R, Blievernicht J, Fischer J, Hofmann U, Bokemeyer C, Eichelbaum M. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-Fu toxicity study group. J Clin Oncol 2008; 26: 2131-2138